Monitor upcoming Phase 2b clinical trial plans for izicopan in hidradenitis suppurativa, which will determine near-term cash needs and potential partnership opportunities. The narrowing loss and extended cash runway reduce near-term dilution risk, but the going concern language warrants caution.
Price Chart
Executive Summary
InflaRx reported Q1 2026 results: no revenue (GOHIBIC sales discontinued Dec 2025), net loss of €5.6M (improved from €8.3M loss in Q1 2025), operating loss of €7.2M (improved from €13.0M), and cash burn reduction. Cash and marketable securities total €39.7M, sufficient into 2027, but going concern uncertainty persists. The filing also notes the planned resignation of CMO Dr. Camilla Chong effective August 2026.
Key Facts
- No revenue generated in Q1 2026 or Q1 2025; commercial activities for GOHIBIC discontinued in December 2025.
- Net loss of €5.6M for Q1 2026 vs. €8.3M loss in Q1 2025, a 33% improvement.
- Operating loss of €7.2M vs. €13.0M a year ago, driven by lower R&D and SG&A expenses after restructuring.
- Cash and cash equivalents of €15.0M plus marketable securities of €24.7M as of March 31, 2026, providing runway into 2027.
- Restructuring announced January 2026 with additional one-time costs of €0.6M in Q1 2026.
- CMO Dr. Camilla Chong to resign effective August 2026; no disagreement cited.
- Material uncertainty about going concern: the company expects to need additional funding to continue operations beyond 12 months.
Financial Impact
Net loss reduced by €2.7M YoY to €5.6M; operating expenses down 45% to €7.5M; cash burn from operations improved to €7.4M from €14.0M.
Risk Factors
- No revenue and ongoing losses require additional financing, likely causing shareholder dilution.
- Failure to advance izicopan through clinical trials could impair long-term value.
- CMO resignation may cause temporary disruption in clinical development oversight.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001140361-26-019211 |
| Document: ef20072108_ex99-2.htm | 0001140361-26-019211 |
| Document: ef20072108_6k.htm | 0001140361-26-019211 |
| Document: 0001140361-26-019211-index-headers.html | 0001140361-26-019211 |
| Document: 0001140361-26-019211-index.html | 0001140361-26-019211 |
| Document: 0001140361-26-019211.txt | 0001140361-26-019211 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers